EUVIMEDEUVIMED entdecken
Open Access

Long-Acting RXR Agonism Preserves Retinal Function and Modulates Inflammation in Diabetic Retinopathy

Emory Johnson, Ehsan Kaffash, Fadeela Sheini, Ashley Rennhack, Micheli Severo Sielski, Assylbek Zhylkibayev, Sergio Li Calzi, Sagun Poudel, Venkatram Atigadda, Qingguo Xu, Maria B Grant iD, Marina S Gorbatyuk iD

Diabetes · 01.09.2026 · 75 (9) · 1554-1567

DOI: 10.2337/db26-0053 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, online erschienen am 16.07.2026. Verfasst von Emory Johnson und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Vision Sciences, The University of Alabama at Birmingham, Birmingham, AL. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Retina, Retinoid X Receptors, Inflammation. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NEI NIH HHS, National Eye Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic retinopathy (DR) is a leading cause of vision loss and is associated with reduced nuclear retinoid X receptor (RXR) activity. Retinal explants exposed to high glucose showed downregulation of RXR, peroxisome proliferator–activated receptor (PPAR), and liver X receptor-β and their lipid metabolism targets (Abca1, Scd1, and Acox1). Supplementation with the RXR agonist UAB126 restored nuclear receptor signaling and preferentially activated RXR/PPAR heterodimers. We evaluated UAB126 microparticles (UAB126-MP), a sustained-release RXR agonist formulation, for pharmacokinetic, molecular, and functional effects in db/db mouse retinas. A single intravitreal injection of UAB126-MP provided extended drug exposure for up to 6 months and increased retinal RXRα expression. Functionally, UAB126-MP preserved scotopic and photopic electroretinographic responses at 2 months and sustained cone photoreceptor function at 6 months. However, it did not reduce acellular capillaries. At 6 months, immunostaining and flow cytometry revealed decreased retinal macrophage/microglial infiltration and reduced CD45-positive myeloid cells and monocytes. These findings indicate that RXR agonism supports neuronal protection and immune modulation but does not prevent vasodegeneration, suggesting primarily neuroprotective and anti-inflammatory actions. Collectively, UAB126-MP confers durable retinal protection through nuclear receptor–mediated pathways, underscoring its potential as a long-acting therapeutic strategy for DR. Article Highlights High glucose exposure of retinal explants reduces expression of nuclear receptors retinoid X receptor (RXR), peroxisome proliferator–activated receptor, and liver X receptor-β, and treatment with UAB126 increases the formation of RXR-peroxisome proliferator–activated receptor heterodimers. Sustained release of UAB126-loaded microparticles enables intravitreal drug delivery for up to 6 months. Intravitreal UAB126 microparticles injection in diabetic mice confers long-term neuroprotection and anti-inflammatory benefits. RXR-targeted therapy represents a promising approach strategy for managing diabetic retinopathy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic RetinopathyRetinaRetinoid X ReceptorsInflammationAnimalsMiceMice, Inbred C57BLMaleElectroretinography

Substanzen

Retinoid X Receptors

Autor:innen und Institutionen

  • Department of Ophthalmology and Vision Sciences, The University of Alabama at Birmingham, Birmingham, AL.
  • Department of Pharmaceutics, Virginia Commonwealth University School of Pharmacy, Richmond, VA.
  • Department of Biochemistry, Wake Forest University School of Medicine, Winston-Salem, NC.
  • Department of Dermatology, The University of Alabama at Birmingham, Birmingham, AL.
  • Department of Ophthalmology, Virginia Commonwealth University School of Medicine, Richmond, VA.

ORCID-Profile: Maria B Grant, Marina S Gorbatyuk

Förderung

  • NCI NIH HHS
  • NEI NIH HHS
  • National Eye Institute

Zitieren

APA

Johnson, E., Kaffash, E., Sheini, F., Rennhack, A., Sielski, M. S., Zhylkibayev, A., Calzi, S. L., Poudel, S., Atigadda, V., Xu, Q., Grant, M. B., & Gorbatyuk, M. S. (2026). Long-Acting RXR Agonism Preserves Retinal Function and Modulates Inflammation in Diabetic Retinopathy. Diabetes, 75(9), 1554-1567. https://doi.org/10.2337/db26-0053

Vancouver

Johnson E, Kaffash E, Sheini F, Rennhack A, Sielski MS, Zhylkibayev A, et al. Long-Acting RXR Agonism Preserves Retinal Function and Modulates Inflammation in Diabetic Retinopathy. Diabetes. 2026;75(9):1554-1567. doi:10.2337/db26-0053

BibTeX
@article{Johnson2026,
  author = {Johnson, Emory and Kaffash, Ehsan and Sheini, Fadeela and Rennhack, Ashley and Sielski, Micheli Severo and Zhylkibayev, Assylbek and Calzi, Sergio Li and Poudel, Sagun and Atigadda, Venkatram and Xu, Qingguo and Grant, Maria B and Gorbatyuk, Marina S},
  title = {Long-Acting RXR Agonism Preserves Retinal Function and Modulates Inflammation in Diabetic Retinopathy},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {9},
  pages = {1554--1567},
  doi = {10.2337/db26-0053}
}
Kostenlos starten →